SuspendedEarly Phase 1

Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation

Stopped: Interim data and power analysis

United States65 participantsStarted 2021-12-01

Plain-language summary

The purpose of this project is to examine the impact of increases in brain insulin on sympathetic nervous system activity, as well as peripheral and cerebral blood flow in humans.

Who can participate

Age range18 Years – 45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * healthy adult men and women; * 18-45 years of age; * BMI \>18 kg/m2; * non-pregnant/non-breastfeeding; * non-nicotine users; Exclusion Criteria: * taking any medications known to affect metabolic, respiratory, cardiovascular, and/or autonomic Self-reported history of: * hepatic, renal, pulmonary, cardiovascular, or neurological disease; * stroke or neurovascular disease; * bleeding/clotting disorders; * sleep apnea or other sleep disorders; * diabetes; * smoking; * history of alcoholism or substance abuse; * hypertension; * respiratory disease; * active cancer; * autoimmune disease.

What they're measuring

Amount of cerebral blood flow

Timeframe: Change from baseline at minute 15

Trial details

NCT IDNCT05153395

SponsorUniversity of Missouri-Columbia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-06

View on ClinicalTrials.gov More Healthy trials